Suppr超能文献

尿崩症:新的诊断概念。

Diabetes Insipidus: New Concepts for Diagnosis.

机构信息

Department of Endocrinology, Diabetology and Metabolism University Hospital Basel, Basel, Switzerland,

Department of Clinical Research, University of Basel, Basel, Switzerland,

出版信息

Neuroendocrinology. 2020;110(9-10):859-867. doi: 10.1159/000505548. Epub 2020 Jan 2.

Abstract

Diabetes insipidus (DI), be it from central or from nephrogenic origin, has to be differentiated from primary polydipsia. This differentiation is crucial since wrong treatment can have dangerous consequences. For decades, the "gold standard" for differential diagnosis has been the standard water deprivation test. However, this test has several limitations leading to an overall limited diagnostic accuracy. In addition, the test has a long duration of 17 h and is cumbersome for patients. Also clinical signs and symptoms and MRI characteristics overlap between patients with DI and primary polydipsia. Direct measurement of arginine vasopressin (AVP) upon osmotic stimulation was first shown to overcome these limitations, but failed to enter clinical practice mainly due to technical limitations of the AVP assay. Copeptin is secreted in equimolar ratio to AVP, mirroring AVP concentrations in the circulation. We have shown that copeptin, without prior fluid deprivation, identifies patients with nephrogenic DI. For the more difficult differentiation between central DI and primary polydipsia, a copeptin level of 4.9 pmol/L stimulated with hypertonic saline infusion differentiates between these 2 entities with a high diagnostic accuracy and is superior to the water deprivation test. However, it is important to note that close and regular sodium monitoring every 30 min during the hypertonic saline test is a prerequisite, which is not possible in all hospitals. Furthermore, side effects are common. Therefore, a nonosmotic stimulation test would be advantageous. Arginine significantly stimulates copeptin and therefore is a novel, so far unknown stimulus of this peptide. Consequently, infusion of arginine with subsequent copeptin measurement was shown to be an even simpler and better tolerated test, but head to head comparison is still lacking.

摘要

尿崩症(DI),无论是中枢性还是肾源性,都必须与原发性多尿症区分开来。这种区分非常重要,因为错误的治疗可能会产生危险的后果。几十年来,区分诊断的“金标准”一直是标准的禁水试验。然而,该试验存在一些限制,导致总体诊断准确性有限。此外,该试验持续时间长达 17 小时,对患者来说很繁琐。此外,DI 和原发性多尿症患者的临床症状和 MRI 特征存在重叠。渗透刺激下精氨酸血管加压素(AVP)的直接测量首先被证明可以克服这些限制,但由于 AVP 测定的技术限制,未能进入临床实践。 copeptin 与 AVP 以等摩尔比例分泌,反映了循环中的 AVP 浓度。我们已经表明,在没有预先进行液体剥夺的情况下,copeptin 可以识别出肾源性 DI 患者。对于更难区分中枢性 DI 和原发性多尿症,高渗盐水输注刺激下 4.9 pmol/L 的 copeptin 水平可以区分这两种疾病,具有较高的诊断准确性,优于禁水试验。然而,需要注意的是,在高渗盐水试验期间每 30 分钟进行密切和定期的钠监测是前提条件,并非所有医院都能做到。此外,副作用很常见。因此,非渗透刺激试验将是有利的。精氨酸可显著刺激 copeptin,因此是这种肽的一种新的、迄今为止未知的刺激物。因此,精氨酸输注后随后进行 copeptin 测量被证明是一种更简单、耐受性更好的试验,但仍缺乏头对头比较。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验